Stockscreener 앱 받기
16.87
0.84%
0.14
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Acadia Pharmaceuticals to Present at J.P. Morgan Healthcare Conference: Pioneering CNS Treatment Innovations - StockTitan
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 2.9%What's Next? - MarketBeat
Schizophrenia Market Predicted to See Upsurge Through 2034, - openPR
State Street Corp Acquires 173,084 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals Awards Stock Options, RSUs to New Hires in Neuroscience Expansion - StockTitan
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Position Reduced by Fmr LLC - MarketBeat
ACADIA Pharmaceuticals' SWOT analysis: stock outlook amid Daybue challenges - Investing.com
Acadia closes on $150M FDA voucher sale - MSN
Y Intercept Hong Kong Ltd Sells 39,245 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Neo Ivy Capital Management Reduces Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals Secures $150M Windfall from Priority Review Voucher Sale, Boosts R&D Pipeline - StockTitan
Pharma Pulse 12/10/24: Did Industry Fumble the DSCSA Deadline? Operationalizing Bispecifics Resources & more - Pharmaceutical Executive
Postoperative Pain Market: Market Outlook, Epidemiology Insights, Therapies, Key Companies in the Market | ACADIA Pharmaceuticals, Adynxx, Apsen Farmaceutica, Arthritis Innovation Corporation, Cali - Barchart
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer - BioSpace
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead - FiercePharma
Acadia Buys Saniona Tremor Drug - San Diego Business Journal
Walleye Capital LLC Has $628,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Brokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat
Pharma Pulse 12/5/24: Gaps in Publicly Funded Non-Inferiority Clinical Trials, Are GLP-1s Eliminating the Need for Bariatric Surgery? & more - Pharmaceutical Executive
The Manufacturers Life Insurance Company Sells 48,809 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Jacobs Levy Equity Management Inc. Sells 143,688 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
BNP Paribas Financial Markets Boosts Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options - MSN
Ryan Reynolds' Latest Film: 'More To Parkinson's' 08/19/2024 - MediaPost Communications
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Erste Asset Management GmbH Makes New $3.80 Million Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Significant Growth in Short Interest - MarketBeat
The week in deals: Acadia taps Saniona for GABRA3 modulator, and more - BioCentury
Rockefeller Capital Management L.P. Has $17.53 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Edgestream Partners L.P. Raises Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
37,683 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Intech Investment Management LLC - MarketBeat
Zacks Research Has Strong Estimate for ACAD FY2024 Earnings - MarketBeat
Acadia signs licensing deal for essential tremor drug candidate - MSN
Fred Alger Management LLC Raises Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Fisher Asset Management LLC Acquires 31,980 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE launch faces hurdles - Investing.com India
Acadia signs deal with Saniona for SAN711 rights - The Pharma Letter
Saniona’s CEO: “The deal with Acadia is significant”BioStock - BioStock - Connecting Innovation and Capital
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET (NASDAQ:ACAD) - Seeking Alpha
Saniona Cash Worries Ease With Acadia Neuro Biobucks Pact - Citeline
ACAD Signs License Deal With Saniona for Rights to Neurology Drug - Yahoo Finance
Acadia licenses Saniona’s SAN711 for essential tremor in deal worth up to $610m - World Pharmaceutical Frontiers
Acadia snaps up an essential tremor drug after field’s summer setbacks - Endpoints News
Acadia signs agreement with Saniona to commercialise SAN711 - Pharmaceutical Technology
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 - BioSpace
Acadia secures Saniona's experimental tremor drug in $600M deal - FirstWord Pharma
Saniona signs license agreement with Acadia Pharmaceuticals for SAN711 - Marketscreener.com
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for San711 - Marketscreener.com
Acadia licenses novel treatment for essential tremor By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711 - MarketWatch
Acadia nabs rights to Saniona's tremor asset in $582M biobucks deal - Fierce Biotech
Acadia licenses novel treatment for essential tremor - Investing.com
Saniona Announces Licensing Agreement with Acadia Pharmaceuticals for SAN711 in Neurological Diseases - Marketscreener.com
ACADIA Pharmaceuticals Inc. Announces Executive Changes - Marketscreener.com
2.88%
2.65%
자본화:
|
볼륨(24시간):